Tango Therapeutics (NASDAQ:TNGX) Trading Down 4.2%

Tango Therapeutics, Inc. (NASDAQ:TNGX)’s stock price dropped 4.2% on Friday . The stock traded as low as $8.00 and last traded at $8.05. Approximately 42,506 shares were traded during trading, a decline of 95% from the average daily volume of 901,850 shares. The stock had previously closed at $8.40.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their target price on Tango Therapeutics from $11.00 to $16.00 in a research note on Friday, August 11th.

Tango Therapeutics Stock Performance

The firm has a 50 day moving average of $8.72 and a two-hundred day moving average of $5.69. The stock has a market cap of $852.64 million, a P/E ratio of -7.53 and a beta of 1.02.

Insider Buying and Selling at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 7,507 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $8.39, for a total value of $62,983.73. Following the completion of the transaction, the insider now owns 81,250 shares of the company’s stock, valued at approximately $681,687.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Boxer Capital, Llc purchased 500,000 shares of the business’s stock in a transaction on Monday, October 16th. The stock was purchased at an average price of $6.84 per share, with a total value of $3,420,000.00. Following the acquisition, the insider now directly owns 8,198,642 shares in the company, valued at approximately $56,078,711.28. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Adam Crystal sold 7,507 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $8.39, for a total value of $62,983.73. Following the completion of the transaction, the insider now directly owns 81,250 shares of the company’s stock, valued at $681,687.50. The disclosure for this sale can be found here. Insiders own 6.20% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

A number of hedge funds have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System acquired a new position in shares of Tango Therapeutics in the 3rd quarter worth approximately $144,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Tango Therapeutics by 205.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 367,357 shares of the company’s stock worth $4,136,000 after buying an additional 247,234 shares in the last quarter. L2 Asset Management LLC acquired a new position in shares of Tango Therapeutics in the 3rd quarter worth approximately $185,000. Barclays PLC raised its holdings in shares of Tango Therapeutics by 56.2% in the 3rd quarter. Barclays PLC now owns 87,882 shares of the company’s stock worth $990,000 after buying an additional 31,618 shares in the last quarter. Finally, Clear Harbor Asset Management LLC raised its holdings in shares of Tango Therapeutics by 22.2% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 20,131 shares of the company’s stock worth $227,000 after buying an additional 3,657 shares in the last quarter. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.